Special Issue

Towards Clinical Interpretation of Metabolomic Data

Message from the Guest Editor

Biochemical diagnosing of human diseases benefits historically from the analysis of and interpretation of metabolite levels in biofluids. They play key diagnostic roles in major diseases ranging from diabetes to a large group of individually rare inherited metabolic diseases. Clinical use of metabolic intermediate levels in biofluid is complicated by many factors known to the biochemist from sampling and metabolite stability up to the heterogeneity of clinical cohorts in biomarker studies. These issues hinder the widespread use of metabolomic data in clinical diagnosing. The volume of the data available for clinical interpretation by the current metabolomic analysis methods allows us to discover data analysis tools that can substantially help with this difficult task. This Special Issue aims to address and solve the problems that hamper the widespread use of metabolomic data in clinical decisions.

Guest Editor

Prof. Dr. Tomáš Adam
Institute of Molecular and Translational Medicine (IMTM), Metabolomic Laboratory, Palacký University, CZ 779 00 Olomouc, Czech Republic

Deadline for manuscript submissions

closed (20 May 2025)



Metabolites

an Open Access Journal by MDPI

Impact Factor 3.7
CiteScore 8.1
Indexed in PubMed

mdpi.com/si/196306

Metabolites
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
metabolites@mdpi.com

mdpi.com/journal/metabolites



Metabolites

an Open Access Journal by MDPI

Impact Factor 3.7
CiteScore 8.1
Indexed in PubMed

mdpi.com/journal/metabolites

MDPI

About the Journal

Message from the Editor-in-Chief

The metabolome is the result of the combined effects of genetic and environmental influences on metabolic processes. Metabolomic studies can provide a global view of metabolism and thereby improve our understanding of the underlying biology. Advances in metabolomic technologies have shown utility for elucidating mechanisms which underlie fundamental biological processes including disease pathology. *Metabolites* is proud to be part of the development of metabolomics and we look forward to working with many of you to publish high quality metabolomic studies.

Editor-in-Chief

Dr. Amedeo Lonardo
Internal Medicine, Ospedale Civile di Baggiovara, Azienda Ospedaliero-Universitaria, 41126 Modena, Italy

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Endocrinology, Diabetes and Metabolism)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 3.6 days (median values for papers published in this journal in the second half of 2025).